Maxime Schmitt
6 Papers
Maxime Schmitt is an academic researcher. The author has contributed to research in topics: Cancer & Internal medicine. The author has co-authored 1 publications.
Chat about Author
Papers
pT3 colorectal cancer revisited: a multicentric study on the histological depth of invasion in more than 1000 pT3 carcinomas—proposal for a new pT3a/pT3b subclassification
Sebastian Foersch,Corinna Lang-Schwarz,Markus Eckstein,Carol Geppert,Maxime Schmitt,Björn Konukiewitz,T. Groll,Felix Schicktanz,Jutta Engel,M. Gleitsmann,Christina C. Westhoff,Nadine Frickel,Anne Sophie Litmeyer,Albert Grass,Paul Jank,Sebastian Lange,Markus Tschurtschenthaler,Dirk Wilhelm,Wilfried Roth,Michael Vieth,Carsten Denkert,Iris D. Nagtegaal,Wilko Weichert,Moritz Jesinghaus +23 more
TL;DR: The histological depth of invasion into the pericolic/perirectal fat was digitally and conventionally measured in a training cohort of 950 colorectal carcinoma (CRC) patients as discussed by the authors .
PITX2 as a Sensitive and Specific Marker of Midgut Neuroendocrine Tumors: Results from a Cohort of 1157 Primary Neuroendocrine Neoplasms.
Albert Grass,A. Kasajima,Sebastian Foersch,Mark Kriegsmann,Alexander Brobeil,Maxime Schmitt,Daniel Wagner,Jelte Poppinga,Dominik Wiese,Elisabeth Maurer,Andreas Kirschbaum,Thomas Muley,H. Winter,Anja Rinke,Thomas M. Gress,Markus Kremer,Matthias Evert,Bruno Märkl,A. Quaas,Markus Eckstein,Markus Tschurtschenthaler,Günter Klöppel,Carsten Denkert,Detlef K Bartsch,Moritz Jesinghaus +24 more
TL;DR: PITX2 is independently validates as a very sensitive and specific immunohistochemical marker of midgut-derived NET in a very large collective of Neuroendocrine Neoplasms and argues towards implementation into diagnostic panels applied for NET as a first line midgut marker.
3
DLL3 Expression in Neuroendocrine Carcinomas and Neuroendocrine Tumours: Insights From a Multicentric Cohort of 1294 Pulmonary and Extrapulmonary Neuroendocrine Neoplasms
Maxime Schmitt,Hanibal Bohnenberger,D. K. Bartsch,Daniel Wagner,Anne Sophie Litmeyer,Albert Grass,A. Rinke,Christine Koch,Marcus Kremer,Matthias Evert,Bruno Märkl,A. Quaas,Markus Eckstein,Konrad Steinestel,Carsten Denkert,Katja Steiger,Günter Klöppel,A. Kasajima,Markus Tschurtschenthaler,Sebastian Foersch,Moritz Jesinghaus +20 more
TL;DR: This study of 1294 neuroendocrine neoplasms (NEN) found DLL3 expression significantly higher in NEC (64.0%) and pulmonary carcinoids (41.5%), but rare in GEP-NET (5.1%) and non-neuroendocrine carcinomas (1.3%), suggesting DLL3-based therapies may be effective in NEC and pulmonary carcinoids.
High expression of insulinoma‐associated protein 1 (INSM1) distinguishes colorectal mixed and pure neuroendocrine carcinomas from conventional adenocarcinomas with diffuse expression of synaptophysin
Anne Sophie Litmeyer,Björn Konukiewitz,A. Kasajima,Sebastian Foersch,Felix Schicktanz,Maxime Schmitt,Franziska Kellers,Albert Grass,Paul Jank,Bettina J. Lehman,Thomas M. Gress,Anja Rinke,D. Bartsch,Carsten Denkert,Wilko Weichert,Günter Klöppel,Moritz Jesinghaus +16 more
- 22 Aug 2023
TL;DR: High expression of INSM1 distinguishes MANEC/NEC from conventional CRCs with diffuse expression of the standard neuroendocrine marker synaptophysin, which do not share the same dismal prognosis, and is supportive for the diagnosis of true colorectal MANEC /NEC.
Stroma areactive invasion front areas (SARIFA) in 1,298 pT3/pT4 colorectal cancers: A strong prognostic parameter complementing established morphological criteria.
Sebastian Foersch,Nuwar Harb,Anne Sophie Litmeyer,Wilfried Roth,Irina Breus,Johannes Schraml,Annika Weiß,Katja Steiger,Julia Teply-Szymanski,Detlef K Bartsch,Carsten Denkert,Maxime Schmitt,Moritz Jesinghaus +12 more
TL;DR: This study of 1,298 pT3/pT4 colorectal cancers found that Stroma Areactive Invasion Front Areas (SARIFA) is a strong prognostic parameter, associated with poor prognosis and adverse clinicopathological features, complementing established morphological criteria.